Welcome to our dedicated page for Kintara Therapeutics SEC filings (Ticker: KTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with the historical Kintara Therapeutics, Inc. (KTRA) listing and its successor TuHURA Biosciences, Inc. (HURA) document a multi-stage corporate and clinical story. Early public disclosures and proxy materials describe Kintara as a San Diego, California–based biopharmaceutical company focused on developing novel solid tumor cancer therapies, with its lead program, REM-001 Therapy, targeting cutaneous metastatic breast cancer (CMBC) through a proprietary photodynamic therapy platform.
Regulatory filings and related press releases provide detail on Kintara’s reverse merger with TuHURA Biosciences, Inc. These documents outline the definitive merger agreement, the structure in which Kayak Mergeco, Inc., a Kintara subsidiary, merged with and into TuHURA, and the resulting status of TuHURA as a direct, wholly owned subsidiary of Kintara prior to the combined company adopting the TuHURA Biosciences, Inc. name. The filings describe stockholder approvals, including a reverse stock split in the range of 1-for-20 to 1-for-40, with a final ratio of 1-for-35, and the expected transition of trading to the Nasdaq Capital Market under the symbol HURA.
Subsequent Form 8-K and 8-K/A reports filed under TuHURA Biosciences, Inc. (HURA) reference the “reverse merger with Kintara Therapeutics, Inc. that closed on October 18, 2024,” confirming completion of the transaction and the continuation of the public company under the TuHURA name. These filings also describe later corporate events, such as TuHURA’s acquisition of Kineta, Inc., pro forma financial information, and private placement financings, all within the HURA reporting framework.
Investors reviewing this filings page can use Stock Titan’s real-time integration with EDGAR to access current and historical 8-Ks, 10-Ks, 10-Qs, and related exhibits that trace the evolution from Kintara Therapeutics to TuHURA Biosciences. AI-powered summaries help explain complex merger agreements, reverse stock split mechanics, Contingent Value Rights arrangements, and subsequent acquisition transactions, highlighting key terms and their implications for equity structure and ownership.
For those researching insider activity and capital structure changes, Form 4 and financing-related filings under the HURA ticker provide additional context on warrant amendments, share issuances, and other equity-linked instruments. Together, these documents form a regulatory history that connects the legacy KTRA oncology-focused entity with the broader immuno-oncology and transaction activity reported by TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. reports that it has advanced its previously announced private placement by securing immediate purchases of approximately $3.2 million from certain investors who had deferred part of their commitment. These investors were originally obligated to buy a remaining portion of a $3.7 million final tranche under a June 2, 2025 securities purchase agreement tied to a larger $12.6 million offering of common stock and warrants.
In return for accelerating the purchase of this final tranche amount, TuHURA agreed to amend existing warrants issued in a 2024 private placement of convertible notes. The company extended the expiration dates of warrants to purchase an aggregate of 1.5 million shares of common stock, moving their expiry out to December 31, 2030. The detailed terms are set out in the final closing and warrant amendment agreements referenced in the report.
KP Biotech Group LLC reported beneficial ownership of 447,232 shares of TuHURA Biosciences, Inc. common stock, representing 0.9% of the outstanding class. The filing states these shares confer sole voting and sole dispositive power over all 447,232 shares and that the stake was not acquired to influence control of the issuer. The percent ownership is calculated using an outstanding share count of 50,046,926 shares reported by the issuer. The filing is a Schedule 13G amendment and affirms the position is below the 5% ownership threshold that would trigger more extensive disclosure.
TuHURA Biosciences, Inc. reported that CA Patel F&F Investments, LLC beneficially owned 447,232 shares of the companys common stock as of June 12, 2025. That holding represents 0.9% of the outstanding class, calculated using 50,046,926 shares reported by the issuer as outstanding on August 11, 2025. The filing states the reporting person has sole voting and dispositive power over all 447,232 shares and that the shares were not acquired to influence control of the company.
The Schedule 13G/A provides the filers business address in Tampa, Florida, and is signed by Adam Baals as Manager of CA Patel F&F Investments, LLC on August 14, 2025.
TuHURA Biosciences completed the acquisition of Kineta, Inc. on June 30, 2025 under the Agreement and Plan of Merger dated December 11, 2024, as amended May 5, 2025. The transaction was structured as a two-step series of mergers: Merger Sub I merged into Kineta (the Surviving Entity), which then merged into Merger Sub II, with Merger Sub II surviving.
This Form 8-K/A amends TuHURA’s original June 30, 2025 report to furnish Item 9.01 financial disclosures. The amendment attaches Kineta’s unaudited consolidated financial statements as of March 31, 2025 and December 31, 2024 as Exhibit 99.1 and provides unaudited pro forma condensed combined financial information for TuHURA as Exhibit 99.2, including a pro forma balance sheet and statements of operations on the noted dates and periods. The filing notes substantially the same financial statements were previously included in TuHURA’s Form S-4, declared effective May 14, 2025. The amendment is signed by CFO Dan Dearborn.
FAQ
What is the current stock price of Kintara Therapeutics (KTRA)?
What is the market cap of Kintara Therapeutics (KTRA)?
